

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Nitric oxide stimulates human sperm motility via activation of the cyclic GMP/protein kinase G signaling pathway

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/79763> since

Published version:

DOI:10.1530/REP-10-0151

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

Reproduction, 141(1):47-54, 2011.

doi: 10.1530/REP-10-0151

The definitive version is available at:

La versione definitiva è disponibile alla URL: <http://www.reproduction-online.org>

Nitric oxide stimulates human sperm motility via activation of the cyclic GMP/protein kinase G signaling pathway.

Erica Miraglia¹, Federico De Angelis², Elena Gazzano¹, Hossain Hassanpour³, Angela Bertagna⁴,
Elisabetta Aldieri¹, Alberto Revelli², and Dario Ghigo^{1*}

¹ Department of Genetics, Biology and Biochemistry, University of Torino, 10126 Torino, Italy

² Reproductive Medicine and IVF Unit, Department of Obstetrical and Gynecological Sciences, University of Torino, S. Anna Hospital, 10126 Torino, Italy

³ Department of Basic Sciences, College of Veterinary Medicine, University of Shahrekord, Shahrekord, Iran

⁴ Department of Internal Medicine, University of Torino, S. Giovanni Battista Hospital, 10126 Torino, Italy

Running head: cGMP signaling and sperm motility

***Corresponding author:**

Dario Ghigo, M.D., Dipartimento di Genetica, Biologia e Biochimica - Sezione di Biochimica, Via Santena, 5/bis - 10126 Torino - Italy (tel. +39-011-6705851; FAX: +39-011-6705845; e-mail: dario.ghigo@unito.it)

Abstract

Nitric oxide (NO), a modulator of several physiological processes, is involved in different human sperm functions. We have investigated whether NO may stimulate the motility of human spermatozoa via activation of the soluble guanylate cyclase (sGC)/cGMP pathway. Sperm samples obtained by masturbation from seventy normozoospermic patients were processed by the swim-up technique. The kinetic parameters of the motile sperm-rich fractions were assessed by computer-assisted sperm analysis. After a 30-90 min incubation, the NO donor S-nitrosoglutathione (GSNO) exerted a significant enhancing effect on progressive motility (77, 78 and 78% vs 66, 65 and 62% of the control at the corresponding time), straight linear velocity (44, 49 and 48 $\mu\text{m/s}$ vs 34, 35 and 35.5 $\mu\text{m/s}$), curvilinear velocity (81, 83 and 84 $\mu\text{m/s}$ vs 68 $\mu\text{m/s}$) and average path velocity (52, 57 and 54 $\mu\text{m/s}$ vs 40, 42 and 42 $\mu\text{m/s}$) at 5 μM but not at lower concentrations, and in parallel increased the synthesis of cGMP. A similar effect was obtained with the NO donor spermine NONOate after 30 and 60 min. The GSNO-induced effects on sperm motility were abolished by ODQ (a specific sGC inhibitor) and mimicked by 8-Br-cGMP (a cell-permeating cGMP analog): the treatment with Rp-8-Br-cGMPS (an inhibitor of cGMP-dependent protein kinases) prevented both the GSNO- and the 8-Br-cGMP-induced responses. On the opposite, we did not observe any effect of the cGMP/PKG pathway modulators on the onset of hyperactivated sperm motility. Our results suggest that NO stimulates human sperm motility via the activation of sGC, the subsequent synthesis of cGMP and the activation of cGMP-dependent protein kinases.

Introduction

70 Nitric oxide (NO) is a free radical gas which participates as a mediator in several
71 physiopathological events, such as regulation of vascular tone, neurotransmission, apoptosis, and
72 inflammation (Wink & Mitchell 1998). NO is synthesized by nitric oxide synthases (NOS), a
73 family of enzymes catalyzing the conversion of L-arginine to L-citrulline and NO with a 1:1
74 stoichiometry (Nathan & Xie 1994). Three NOS isoforms have been described: endothelial
75 (eNOS, NOS III), neuronal (nNOS, NOS I) and inducible (iNOS or NOS II) (Nathan & Xie
76 1994). NO has been demonstrated to play a role in a variety of functions in the human
77 reproductive tract, including sperm motility (Lewis *et al.* 1996), chemotaxis (Miraglia *et al.*
78 2007), and sperm-zona pellucida binding ability (Sengoku *et al.* 1998). NOS isoforms have been
79 localized in the acrosome and tail of human, mouse and bovine spermatozoa (Herrero *et al.* 1996;
80 Meiser & Schulz 2003), and low motility spermatozoa have been shown to exhibit aberrant
81 patterns of eNOS immunostaining (O'Bryan *et al.* 1998). It has been reported that low
82 concentrations of NO (25-100 nM sodium nitroprusside) enhance the motility of human
83 spermatozoa (Hellstrom *et al.* 1994; Zhang & Zheng 1996). Accordingly, human sperm motility
84 is inhibited by the NOS inhibitor N^G-nitro-L-arginine methyl ester and by the NO scavenger
85 methylene blue (Lewis *et al.* 1996; Donnelly *et al.* 1997). On the other hand, high NO
86 concentrations (25-125 µM pure nitric oxide, 0.25-2.5 mM sodium nitroprusside, 12-600 µM S-
87 nitroso-N-acetylpenicillamine, 100-125 µM 3-morpholinosydnonimine) seem to exert opposite
88 effects on the motility of human spermatozoa *in vitro* (Rosselli *et al.* 1995; Nobunaga *et al.* 1996;
89 Weinberg *et al.* 1995). Studies on sperm capacitation showed that NO (1-100 µM spermine
90 NONOate or diethylamine-NONOate) increases cAMP levels, thus triggering protein kinase A
91 activation and tyrosine phosphorylation (Herrero *et al.* 2000) and is also involved in activation of
92 protein extracellular signal regulated kinases (ERKs) (Thundathil *et al.* 2003; O'Flaherty *et al.*

2006). On the other hand, like in many other cell types, NO activates the soluble guanylate cyclase (sGC) in human spermatozoa (Revelli *et al.* 2002). The NO donors sodium nitroprusside and spermine-NONOate have been shown to increase the intracellular levels of cGMP in human (Zhang & Zheng 1996; Revelli *et al.* 2001) and murine (Herrero *et al.* 1998) spermatozoa, respectively, and recently the sGC has been identified in human sperm by immunoblotting (Willipinski-Stapelfeldt *et al.* 2004). Although its levels in human sperm are about 100-fold lower than the cAMP content (Willipinski-Stapelfeldt *et al.* 2004), cGMP has been implicated in several sperm signaling pathways functions, such as capacitation, acrosome reaction, chemotaxis and sperm-egg interaction (Revelli *et al.* 2001; Revelli *et al.* 2002, Herrero *et al.* 2003; Miraglia *et al.* 2007). cGMP is thought to modulate also sperm motility. Indeed, the cGMP-dependent phosphodiesterase (PDE) inhibitor sildenafil was reported by some authors (Lefievre *et al.* 2000; Cuadra *et al.* 2000), but not by others (Andrade *et al.* 2000; Aversa *et al.* 2000; Burger *et al.* 2000), to increase the velocity and amplitude of lateral head displacement in human spermatozoa. Lefievre *et al.* observed an inhibition of sperm PDE activity with sildenafil at high concentrations, able to inhibit many PDE and causing also an increase of cAMP (Lefievre *et al.* 2000), whereas Cuadra *et al.* reported that sildenafil stimulates sperm motility at much lower concentrations, quite close to the IC₅₀ of sildenafil for the cGMP-dependent PDE (Cuadra *et al.* 2000). A recent review of *ex vivo* studies suggests that sildenafil and tadalafil exert a dose-dependent effect on sperm motility which is enhanced at low doses but may be reduced at high concentrations, but further investigations are required to evaluate the mechanisms by which these phosphodiesterase selective inhibitors modulate sperm motility (Dimitriadis *et al.* 2008).

Until now no clear data show a direct relationship between exposure to NO, increase of sperm cGMP levels and changes of human sperm motility. Therefore, aim of this study has been to investigate whether human sperm motility, which is considered one of the most significant

fertility-related sperm features (Hirano *et al.* 2001), may be affected by NO via activation of the sGC/cGMP signaling pathway.

RESULTS

Since the swim-up procedure was performed in SWM containing bicarbonate and albumin, as previously described (Miraglia *et al.* 2010), for a time sufficient to induce capacitation in most sperm cells, the experiments shown in each point of this paper can be considered as performed on capacitated spermatozoa (see also Materials and Methods section). Preliminary experiments of dose-dependence were performed to establish the concentration of the NO donor GSNO able to affect human sperm motility patterns. A progressively motile sperm swims forward in an essentially straight line: rapid progressive motility (A) indicates sperm swimming with a progression velocity $> 25 \mu\text{m/s}$, while slow progressive motility (B) indicates sperm swimming with a progression velocity $= 5\text{-}25 \mu\text{m/s}$ (Krause & Viethen 1999). At the concentration of $5 \mu\text{M}$, GSNO exerted a significant enhancing effect on progressive motility (A + B motility classes) at each time period considered, while at $0.1\text{-}1 \mu\text{M}$ it was not effective (Fig. 1A). When the spermatozoa were incubated with $10 \mu\text{M}$ GSNO, progressive motility (A + B classes) was comparable to those of untreated sperm (Fig 1A). To check how long the effect of $5 \mu\text{M}$ GSNO takes to develop, time-dependence experiments were performed. The increase of sperm motility induced by GSNO was not significant at 10 and 20 minutes, but only after an at least 30 minutes incubation (Fig 1B). Analyzing each class of motility we observed that the increase of progressive motility (WHO classes A + B) after treatment with GSNO was mainly due to a significant rise in the percentage of A class spermatozoa, which was counterbalanced by a parallel decrease of both C and D class spermatozoa; the amount of spermatozoa exhibiting a B pattern of motility did not change under all the experimental conditions (data not shown). On the

contrary, the motion parameters linearity (LIN) and straightness (STR) were unaffected, and no induction of HA was observed (data not shown).

In the same way, GSNO strongly increased the individual parameters of sperm movement straight linear velocity (VSL), curvilinear velocity (VCL) and average path velocity (VAP) when added at 5 μ M but not at 0.1-1 μ M (data not shown). After the incubation with 10 μ M GSNO, VSL, VCL and VAP were comparable to those of untreated sperm, thus suggesting that GSNO at this concentration was not yet toxic, but it neither could improve the sperm motility (data not shown). Spermine NONOate (SPNO) is a faster NO donor than GSNO: when incubated with several samples (n = 6) of spermatozoa, SPNO 0.5 μ M significantly increased the progressive motility (A + B classes) after 30 (71.2 ± 2 % vs. 51 ± 1 % in controls) and 60 min (69 ± 3 % vs. 50 ± 2 % in controls). In the same experimental conditions 0.5 μ M SPNO increased significantly also VSL, VCL and VAP (data not shown).

Oxidized glutathione (GSSG), the product of GSNO decomposition, is a powerful chelator of copper ions (Singh *et al.* 1999). Since copper ions can influence the release of NO from GSNO, we performed further experiments to check whether the increased sperm motility that we observed after incubation with GSNO is due to the chelation of copper by GSSG. We measured sperm motility in the presence of 5 μ M reduced glutathione (GSH) or GSSG, to exclude that glutathione per se, in any form, could alter the progressive motility: both GSH and GSSG had no significant effect on sperm motility (n = 4; data not shown). To chelate copper we performed also other experiments with 1 mM EDTA, and even in this case we did not observe any significant modification vs. controls and vs. GSNO alone (n = 4; data not shown). After EDTA treatment the level of calcium was about 1 mM.

Thereafter, the 5 μ M concentration of GSNO was chosen to perform the subsequent experiments. The NO donor induced a significant increase of sperm progressive motility

measured by CASA after incubation with freshly ejaculated human samples for 30, 60 and 90 min (Fig. 2). The sGC inhibitor ODQ did not affect the progressive motility when added alone, but completely blunted its GSNO-elicited increase at each time period (Fig. 2). On the other hand, 8-Br-cGMP, a cell-permeating cGMP analog, exerted a significant enhancing effect on progressive motility *per se* and completely reversed the inhibitory effect of ODQ on the GSNO-stimulated increase (Fig. 2). Finally, the PKG inhibitor Rp-8-Br-cGMPS, which *per se* did not modify the sperm progressive motility, abolished the effects of GSNO and 8-Br-cGMP on this motion parameter (Fig. 2).

In order to confirm the role of NO in this process, we measured also the progressive motility in the presence of the NO scavenger PTIO. 100 μ M PTIO did not affect sperm motility when used alone, but when co-incubated with GSNO (5 μ M) it completely reversed the increase of motility induced by GSNO (Fig. 3). In the presence of 20 μ l of packed fresh red blood cells, used as reservoirs of the NO scavenger oxyhemoglobin, the motility results were the same observed with PTIO (n = 3; data not shown). To this purpose, we incubated the spermatozoa at the reported concentrations used in the other experiments and for the indicated times (30, 60, 90 min) in the lower compartment of a transwell system (having a polycarbonate transwell insert membrane with pore sizes of 3 μ m, in 24 well plates provided by Corning Incorporated, Apton, MA), containing in the upper compartment 20 μ l of packed fresh red blood cells in 0.5 ml of SWM. After each incubation time the upper compartment was taken out and the sperm motility parameters were measured as described in the Materials and Methods section.

We also evaluated the effect of NO on sperm kinetic parameters assessed by CASA. In the presence of GSNO, the straight linear velocity (VSL) markedly increased, an effect that was abolished by ODQ (which *per se* did not modify this motion parameter), as shown in Fig. 4A; the cGMP analog 8-Br-cGMP significantly stimulated VSL, and bypassed the inhibition exerted by

ODQ on the GSNO-evoked VSL increase (Fig. 4A). The co-incubation with Rp-8-Br-cGMPS completely blunted the positive action of both GSNO and 8-Br-cGMP on VSL (Fig. 4A).

The same pattern of response was observed when considering the curvilinear velocity (VCL) (Fig. 4B) and the average path velocity (VAP) (Fig. 4C) of human spermatozoa treated under the same experimental conditions.

Finally, under the same experimental conditions GSNO significantly increased the synthesis of cGMP in human spermatozoa at each incubation time considered: the absence of a significant time-dependence suggests that GSNO exerts a maximal effect already after 30 min, and that between 30 and 90 min the synthesis of cGMP is maintained in a steady state condition. The effect of GSNO was completely abolished by ODQ; as expected, after incubation with 8-Br-cGMP, both alone and together with GSNO and ODQ, the cGMP intracellular level was significantly higher than the control level (Fig. 5). Also in this case, no time-dependence was observed, suggesting that in our experimental conditions the entry of 8-Br-cGMP into the cells and its degradation were balanced throughout the time of investigation.

Since the measurement of intracellular cGMP was performed in the presence of the phosphodiesterase inhibitor IBMX to inhibit cGMP hydrolysis, we performed further motility experiments on samples pre-treated for 20 min with 200 μ M IBMX and then for 30, 60 and 90 min with 5 μ M GSNO: we observed that the pre-treatment with IBMX did not influence the enhancement of sperm motility induced by NO (Fig. 3).

DISCUSSION

The nitric oxide/cGMP signaling pathway modulates several physiopathological events of the mammalian reproductive tract (Rosselli *et al.* 1998). As far as sperm functions are concerned, NO released by sodium nitroprusside has been shown to play an important role in mouse sperm

hyperactivation (Herrero *et al.* 1994) and in the maintenance of post-thaw human sperm motility and viability (Hellstrom *et al.* 1994). Moreover, spermatozoa themselves synthesize NO, and the basal release of this free radical by spermatozoa has been observed to be higher in normozoospermic than in asthenospermic sperm samples; accordingly, normal spermatozoa express more eNOS and generate more nitrite than spermatozoa of asthenospermic samples (Lewis *et al.* 1996). Furthermore, the NO scavenger methylene blue and the NOS inhibitor N^G-nitro-L-arginine methyl ester have been shown to inhibit human sperm motility (Lewis *et al.* 1996; Donnelly *et al.* 1997). On the other hand, when female mice null for one of the three NOS isoforms (eNOS, nNOS and iNOS, respectively) mated with null male mice the rate of in vitro fertilization was not inhibited (Yang *et al.* 2005): this observation does not change the meaning of our results, because in the absence of a NOS isoform NO can be produced by another isoform. Furthermore, these results were obtained in mice. Finally, in spermatozoa NO can be generated as a consequence of a direct hydrogen peroxide attack on arginine (Aitken *et al.* 2004).

In the present work we provide further evidence suggesting a role of the cGMP signaling pathway in human sperm motility. The NO donor GSNO significantly increased the sperm forward progressive motility after 30-90 min of incubation: GSNO significantly augmented the percentage of A class sperm without modifying the overall amount of B class sperm; it also decreased the percentage of *in situ* motile (C class) and immotile (D class) cells. In parallel, the NO donor stimulated the sperm kinetic parameters assessed by CASA, straight linear velocity (VSL), curvilinear velocity (VCL) and average path velocity (VAP). This is in accordance with a previous study reporting that sodium nitroprusside increased human sperm motility (Zhang & Zheng 1996): such effect was detectable at 25-100 nM but not at 200-400 nM, whereas we observed a significant motility enhancement using 5 µM GSNO. This difference may be due to the different NO donor employed and the different experimental procedure used to measure

sperm motility: indeed, that study evaluated a trans-membrane migration ratio (the proportion of human spermatozoa moving across a membrane separating two chambers) (Zhang & Zheng 1996), whereas CASA calculates the percentage of cells exhibiting a forward progressive motility and the kinetic parameters of each cell.

Compared to GSNO (having an half-life of hours, ranging from 10 to 38 h) (Nikitovic & Holmgren 1996; Mancuso *et al.* 2003), SPNO is a faster NO donor, with a half-life of 39 minutes at 37°C and pH 7.4 (Keefer *et al.* 1996). In further experiments using SPNO as NO donor, we observed that also the incubation with SPNO 0.5 μ M significantly increased the progressive motility (A + B classes), VSL, VCL and VAP after 30 and 60 min.

In a previous work we demonstrated that GSNO and 8-Br-cGMP exerted a significant chemotactic effect on human spermatozoa without affecting their motion parameters (Miraglia *et al.* 2007). In that study both substances were used at different concentrations and time periods compared to those employed in this investigation: GSNO exerted a chemoattractant effect at 100 nM, while in this study it was ineffective on motility even at 1 μ M. On the other hand, 8-Br-cGMP was used in the previous study at a 1 mM concentration, two-fold higher than the one used in the present work. Moreover, in our previous work we investigated the sperm motion parameters only after 20 min of incubation with GSNO and 8-Br-cGMP, whereas in the present research we employed longer (30-90 min) time periods of observation (Miraglia *et al.* 2007). Since the intracellular levels of cGMP measured after incubation with either GSNO or 8-Br-cGMP were respectively similar in both experimental works, in spite of the different incubation times and concentrations used, it is likely that these compounds exert a significant effect on sperm motility only when the level of intracellular cGMP is maintained increased for a time longer than the one necessary for cGMP to modulate chemotaxis. This suggestion may make sense, since it is reasonable to suppose that at a first time sperm needs to be simply oriented

versus a source of NO and only subsequently, when the increase of cGMP shows to be persistently high, the motility should increase.

The effect of GSNO on sperm motility is indeed mediated by an increased synthesis of cGMP, as the sGC inhibitor ODQ blunted the GSNO-elicited motility and abolished the increase of intracellular cGMP induced by GSNO. The treatment with the cell-permeating cGMP analog 8-Br-cGMP, which augmented by nearly 4-fold the intracellular content of cyclic nucleotide, strongly increased the forward progressive motility and the kinetic parameters VSL, VCL and VAP. Moreover, 8-Br-cGMP reversed the inhibitory effect of ODQ on the GSNO-evoked increase of progressive motility and velocity, confirming that ODQ inhibited sperm motility by lowering the intracellular level of cGMP.

Taken together, these findings suggest that NO stimulates human sperm motility via the activation of sGC and the subsequent synthesis of cGMP. One of the main targets of cGMP in many tissues is a family of serine/threonine kinases, the PKGs (Hofmann 2005). Rp-8-Br-cGMPS, a PKG inhibitor (Kawada *et al.* 1997), abolished the positive effect exerted by both GSNO and 8-Br-cGMP on sperm motility, suggesting that the effect of endogenous or exogenous cGMP on sperm movement is mediated by PKG activity. Thus, from our data PKG seems to play a role in mediating not only the NO-elicited chemotaxis and the acrosome reaction (Miraglia *et al.* 2007; Revelli *et al.* 2001), but also in modulating several sperm motion patterns. On the other hand, we did not observe any effect of the cGMP/PKG pathway modulators on the onset of hyperactivated sperm motility.

It is widely acknowledged that spermatozoa in the human female reproductive tract have close and prolonged contact with a significant array of NO-producing cells (Rosselli *et al.* 1998; Sun *et al.* 2005; Machado-Oliveira *et al.* 2008); the exact sites of NO production in the female genital tract remain to be investigated, but Machado-Oliveira and colleagues (Machado-Oliveira *et al.*

2008) showed that detectable amounts of NO are produced in human cumulus fragments and oviduct explants. This free radical is relatively unreactive, and is able to diffuse from the cell in which it is generated to the neighbor cells, covering long distances in a very short time (Kröncke *et al.* 1997). Moreover, spermatozoa themselves produce and release NO during their trip along the upper female genital tract. This suggests that a complex interaction between spermatozoa, granulosa cells and other cells of the female reproductive tract may submit human sperm to amounts of NO that are sufficient to elicit *in vivo* the changes of motility we have observed *in vitro*.

It is generally accepted that a good sperm motility is a major component of normal male fertility. Men with poorly motile or immotile sperm are typically infertile or sterile (Turner 2006). A deeper knowledge of the role of the NO/cGMP/PKG signaling pathway in the physiopathology of sperm motility could help to pharmacologically improve the fertilization capacity of human sperm or, alternatively, could lead to the development of an effective and safe male contraceptive based on sperm motility impairment.

Materials and methods

Reagents

Sperm Washing Medium (SWM) was supplied by Celbio (Milan, Italy): it is based on the Modified Human Tubal Fluid (Quinn *et al.* 1985), containing sodium bicarbonate (4 mM), Hepes buffer (21 mM), human serum albumin (5 mg/ml). S-nitrosoglutathione (GSNO), 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ), 8-bromo-cGMP (8-Br-cGMP), and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma Chemical Co. (St. Louis, MO). The inhibitor of cGMP-dependent protein kinases (PKGs) 8-bromoguanosine-3',5'-monophosphorothioate Rp-isomer (Rp-8-Br-cGMPS) was from Biolog Life Science Institute

(Bremen, Germany). The [^3H]cGMP RIA kit was obtained from Amersham International (Buckinghamshire, UK).

Collection and preparation of sperm samples

Sperm samples were obtained by masturbation after 3-5 days of sexual abstinence from seventy normozoospermic patients belonging to couples presenting for infertility evaluation. Each donor gave informed consent allowing the use of his semen for our experiments. The Institutional Review Board approval was obtained from the internal ethical committee that authorized the use of semen samples submitted to semen examination for experimental purposes. All samples were allowed to liquefy for at least 30 minutes at 37°C, then they were evaluated for sperm concentration, motility and morphology according to World Health Organization guidelines (World Health Organization 2001). Only specimens with normal parameters (concentration > 20 x 10⁶ spermatozoa/ml, progressive motility > 50%) were used in the experiments.

Motile spermatozoa were capacitated by the swim-up technique (37°C for 75 min in a 5% CO₂ atmosphere) using SWM, as previously described (Miraglia *et al.* 2010). The presence of round cells was initially below 1x10⁶ in all sperm samples, and was minimal if not absent after the swim-up technique in the final suspension. After swim-up, the motile sperm-rich fraction was centrifuged at 600 g for 10 min, the supernatant was discarded and the pellet re-suspended in SWM. The concentration of the spermatozoa suspensions was assessed in a Makler counting chamber (Sefi Medical Instruments, Haifa, Israel) under a phase-contrast microscope (magnification 20 X), and adjusted to approximately 100 x 10⁶ cells/ml. The dose-dependent effect of GSNO on sperm motility was investigated in the first 25 samples (20x10⁶ cells/200 µl), the effect of the modulation of the cGMP pathway on sperm kinetic parameters was studied in the subsequent 40 samples (20x10⁶ cells/200 µl), and finally the ability of the cGMP-modulating

agents to modify the intracellular cGMP content was checked in the last 5 samples (15×10^6 cells/500 μ l). GSNO was not toxic at the concentrations used, as checked by the eosin Y exclusion test (Cincik *et al.* 2007).

Analysis of Motility Parameters

Aliquots of sperm suspension (200 μ l) in SWM, each containing 20×10^6 cells, were incubated under the experimental conditions indicated in Results. Sperm motility parameters were assessed by computer-assisted sperm analysis (CASA) (CGA-WLJY-9000, CGA Distribution, Florence, Italy) after 30, 60 and 90 min of incubation. The following kinetic parameters were measured: percentage of spermatozoa exhibiting a forward progressive motility (A+B WHO classes), in situ motility (C WHO class), or no motility (D WHO class); straight linear velocity (VSL, which represents the average velocity, expressed in μ m/s, measured from the beginning to the end of a linear track); curvilinear velocity (VCL, which is the average velocity measured over the actual point-to-point track followed by the cell, expressed as μ m/s); average path velocity (VAP, corresponding to the average velocity of smoothed cell's pathway, expressed in μ m/s); linearity [$\text{LIN} = (\text{VSL}/\text{VCL}) \times 100$]; straightness (STR, the percentage of correspondence of the cell's pathway to a straight line, with 100% corresponding to the maximal extent of straightness) (Mortimer 1997). Sperm hyperactivation (HA) was also considered, using the following parameters: $\text{VCL} \geq 70 \mu\text{m/s}$, $\text{ALH} \geq 7 \mu\text{m}$, $\text{LIN} \leq 30\%$, $\text{VSL} \leq 30 \mu\text{m/s}$ (Green & Fishel 1999).

Measurement of intracellular cGMP

The level of intracellular cGMP was measured as previously described (Miraglia *et al.* 2007). Briefly, aliquots of sperm suspensions (500 μ l), each containing 15×10^6 cells, were pre-treated for 20 min with the phosphodiesterase inhibitor IBMX (200 μ M) to inhibit cGMP hydrolysis, and then were co-incubated for 30, 60 or 90 min with the same substances (GSNO, ODQ, 8-Br-cGMP) used for the assessment of motility parameters, alone or differently combined.

Subsequently, the samples were centrifuged at 13,000 g for 1 min, the supernatants were discarded and 50 µl of absolute ethanol were added to the pellets; ethanol was then evaporated by vacuum centrifugation, and 350 µl of Tris/EDTA buffer (50 mM Tris-HCl, 4 mM EDTA, pH 7.5) were added. After 10 min, 100 µl of supernatant were tested for the cGMP level with a [³H]cGMP immunoassay system. The cGMP content was expressed as pmol/10⁶ cells. Cross-reactivity of the [³H]cGMP immunoassay system with cAMP was less than 0.001%.

Statistical analysis

All data are provided as means ± SEM. The results were analyzed by a One-Way Analysis of Variance (ANOVA) and Tukey's and Bonferroni's test (software: SPSS 11.0 for Windows, SPSS Inc., Chicago, IL), including the different times of incubation in the global significance evaluation. A *p* value < 0.05 was considered significant.

Declaration of interest.

There is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding.

This research was supported by grants from Regione Piemonte (Ricerca Sanitaria Finalizzata) and Ministero dell'Istruzione, dell'Università e della Ricerca, Italy.

References

Aitken RJ, Ryan AL, Baker MA & McLaughlin EA 2004 Redox activity associated with the maturation and capacitation of mammalian spermatozoa. *Free Radical Biology and Medicine* **36** 994-1010.

381 Andrade JR, Traboulsi A, Hussain A & Dubin NH 2000 *In vitro* effects of sildenafil and
382 phentolamine, drugs used for erectile dysfunction, on human sperm motility. *American*
383 *Journal of Obstetrics & Gynecology* **182** 1093-1095.

384 Aversa A, Mazzilli F, Rossi T, Delfino M, Isidori AM & Fabbri A 2000 Effects of sildenafil
385 (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal
386 males. *Human Reproduction* **15** 131-134.

387 Burger M, Sikka SC, Bivalacqua TJ, Lamb DJ & Hellstrom WJ 2000 The effect of sildenafil on
388 human sperm motion and function from normal and infertile men. *International Journal of*
389 *Impotence Research* **12** 229-234.

390 Cincik M, Ergur AR, Tutuncu L, Muhcu M, Kilic M, Balaban B & Urman B 2007 Combination
391 of hypoosmotic swelling/eosin Y test for sperm membrane integrity evaluation: correlations
392 with other sperm parameters to predict ICSI cycles. *Archives of Andrology* **53** 25-28.

393 Cuadra DL, Chan PJ, Patton WC, Stewart SC & King A 2005 Type 5 phosphodiesterase
394 regulation of human sperm motility *American Journal of Obstetrics & Gynecology* **182** 1013-
395 1015.

396 Dimitriadis F, Giannakis D, Pardalidis N, Zikopoulos K, Paraskevaïdis E, Giotitsas N, Kalaboki
397 V, Tsounapi P, Baltogiannis D, Georgiou I *et al.* 2008 Effects of phosphodiesterase-5
398 inhibitors on sperm parameters and fertilizing capacity. *Asian Journal of Andrology* **10** 115-
399 133.

400 Donnelly ET, Lewis SEM, Thompson W & Chakravarthy U 1997 Sperm nitric oxide and
401 motility: the effects of nitric oxide synthase stimulation and inhibition. *Molecular Human*
402 *Reproduction* **3** 755-762.

403 Green S & Fishel S 1999 Morphology comparison of individually selected hyperactivated and
404 non-hyperactivated human spermatozoa. *Human Reproduction* **14** 123-130.

405 Hellstrom WJG, Bell M, Wang R & Sikka SC 1994 Effects of sodium nitroprusside on sperm
 406 motility, viability and lipid peroxidation. *Fertility and Sterility* **61** 1117-1122.

407 Herrero MB, Cebal E, Boquet M, Viggiano JM, Vitullo A & Gimeno MA 1994 Effect of nitric
 408 oxide on mouse sperm hyperactivation. *Acta Physiologica Pharmacologica et Therapeutica*
 409 *Latinoamericana* **44** 65-69.

410 Herrero MB, Chatterjee S, Lefièvre L, de Lamirande E & Gagnon C 2000 Nitric oxide interacts
 411 with the cAMP pathway to modulate capacitation of human spermatozoa. *Free Radical*
 412 *Biology and Medicine* **29** 522-536.

413 Herrero MB, Cebal E, Franchi A, Motta A & Gimeno MF 1998 Progesterone enhances
 414 prostaglandin E₂ production via interaction with nitric oxide in the mouse acrosome reaction.
 415 *Biochemical Biophysical Research Communication* **252** 324-328.

416 Herrero MB, de Lamirande E & Gagnon C 2003 Nitric oxide is a signaling molecule in
 417 spermatozoa. *Current Pharmaceutical Design* **9** 419-425.

418 Herrero MB, Perez Martinez S, Viggiano JM, Polak JM & de Gimeno MF 1996 Localization by
 419 indirect immunofluorescence of nitric oxide synthase in mouse and human spermatozoa.
 420 *Reproduction Fertility and Development* **8** 931-934.

421 Hirano Y, Shibahara H, Obara H, Suzuki T, Takamizawa S, Yamaguchi C, Tsunoda H & Sato I
 422 2001 Relationships between sperm motility characteristics assessed by the computer-aided
 423 sperm analysis (CASA) and fertilization rates in vitro. *Journal of Assisted Reproduction and*
 424 *Genetics* **18** 213-218.

425 Hofmann F 2005 The biology of cyclic GMP-dependent protein kinases. *Journal of Biological*
 426 *Chemistry* **280** 1-4.

427 Kawada T, Toyosato A, Islam MO, Yoshida Y & Imai S 1997 cGMP-kinase mediates cGMP-
 428 and cAMP-induced Ca^{2+} desensitization of skinned rat artery. *European Journal of*
 429 *Pharmacology* **323** 75-82.

430 Keefer LK, Nims RW, Davies KM & Wink DA 1996 “NONOates” (1-substituted diazen-1-ium-
 431 1,2-diulates) as nitric oxide donors: convenient nitric oxide dosage forms. *Methods in*
 432 *Enzymology* **268** 281-293.

433 Krause W & Viethen G 1999 Quality assessment of computer-assisted semen analysis (CASA) in
 434 the andrology laboratory. *Andrologia* **31** 125-129.

435 Kröncke KD, Fehsel K & Kolb-Bachofen V 1997 Nitric oxide: cytotoxicity versus cytoprotection
 436 - how, why, when, and where? *Nitric Oxide* **1** 107-120.

437 Lefievre L, DeLamirande E & Gagnon C 2000 The cyclic GMP-specific phosphodiesterase
 438 inhibitor, sildenafil, stimulates human sperm motility and capacitation but not acrosome
 439 reaction. *Journal of Andrology* **21** 929-937.

440 Lewis SEM, Donnelly ET, Sterling ESL, Kennedy MS, Thompson W & Chakravarthy U 1996
 441 Nitric oxide synthase and nitrite production in human spermatozoa: evidence that endogenous
 442 nitric oxide is beneficial to sperm motility. *Molecular and Human Reproduction* **2** 873-878.

443 Machado-Oliveira G, Lefievre L, Ford C, Herrero MB, Barratt C, Connolly TJ, Nash K, Morales-
 444 Garcia A, Kirkman-Brown J & Publicover S 2008 Mobilisation of Ca^{2+} stores and flagellar
 445 regulation in human sperm by S-nitrosylation: a role for NO synthesised in the female
 446 reproductive tract. *Development* **135** 3677-3686.

447 Mancuso C, Bonsignore A, Di Stasio E, Mordente A & Motterlini R 2003 Bilirubin and S-
 448 nitrosothiols interaction: evidence for a possible role of bilirubin as a scavenger of nitric
 449 oxide. *Biochemical Pharmacology* **66** 2355-2363.

450 Meiser H, Schulz R 2003 Detection and localization of two constitutive NOS isoforms in bull
 451 spermatozoa. *Anatomia Histologia Embryologia* **32** 321-325.

452 Miraglia E, Rullo ML, Bosia A, Massobrio M, Revelli A & Ghigo D 2007 The stimulation of
 453 nitric oxide/cyclic GMP signaling pathway elicits human sperm chemotaxis in vitro. *Fertility
 454 and Sterility* **87** 1059-1063.

455 Miraglia E, Lussiana C, Viarisio D, Racca C, Cipriani A, Gazzano E, Bosia A, Revelli A &
 456 Ghigo D 2010 The pentose phosphate pathway plays an essential role in supporting human
 457 sperm capacitation. *Fertility and Sterility* **93** 2437-2340.

458 Mortimer ST 1997 A critical review of the physiological importance and analysis of sperm
 459 movement in mammals. *Human Reproduction Update* **3** 403-439.

460 Nathan C & Xie QW 1994 Nitric oxide synthases: roles, tolls, and controls. *Cell* **78** 915-918.

461 Nikitovic D & Holmgren A 1996 S-nitrosoglutathione is cleaved by the thioredoxin system with
 462 liberation of glutathione and redox regulating nitric oxide. *Journal of Biological Chemistry*
 463 **271** 19180-19185.

464 Nobunaga T, Tokugawa Y, Hashimoto K, Kubota Y, Sawai K, Kimura T, Shimoya K, Takemura
 465 M, Matsuzaki N, Azuma C *et al.* 1996 Elevated nitric oxide concentration in the seminal
 466 plasma of infertile males: nitric oxide inhibits sperm motility. *American Journal of
 467 Reproductive Immunology* **36** 193-197.

468 O'Bryan MK, Zini A, Cheng CY & Schlegel PN 1998 Human sperm endothelial nitric oxide
 469 synthase expression: correlation with sperm motility. *Fertility and Sterility* **70** 1143-1147.

470 O'Flaherty C, de Lamirande E & Gagnon C 2006 Reactive oxygen species modulate independent
 471 protein phosphorylation pathways during human sperm capacitation. *Free Radical Biology
 472 and Medicine* **40** 1045-1055.

473 Quinn P, Kerin JF & Warnes GM 1985 Improved pregnancy rate in human in vitro fertilization
 474 with the use of a medium based on the composition of human tubal fluid. *Fertility and*
 475 *Sterility* **44** 493-498.

476 Revelli A, Costamagna C, Moffa F, Aldieri E, Ochetti S, Bosia A, Massobrio M, Lindblom B &
 477 Ghigo D 2001 Signaling pathway of nitric oxide-induced acrosome reaction in human
 478 spermatozoa. *Biology of Reproduction* **64** 1708-1712.

479 Revelli A, Ghigo D, Moffa F, Massobrio M & Tur-Kaspa I 2002 Guanylate cyclase activity and
 480 sperm function. *Endocrine Reviews* **23** 484-494.

481 Rosselli M, Dubey RK, Imithurn B, Macas E & Keller PJ 1995 Effects of nitric oxide on human
 482 spermatozoa: evidence that nitric oxide decreases sperm motility and induces sperm toxicity.
 483 *Human Reproduction* **10** 1786-1790.

484 Rosselli M, Keller PJ & Dubey RK 1998 Role of nitric oxide in the biology, physiology and
 485 pathophysiology of reproduction. *Human Reproduction Update* **4** 3-24.

486 Sengoku K, Tamate K, Yoshida T, Takaoka Y, Miyamoto T & Ishikawa M 1998 Effects of low
 487 concentrations of nitric oxide on the zona pellucida binding ability of human spermatozoa.
 488 *Fertility and Sterility* **69** 522-527.

489 Singh RJ, Hogg N, Goss SPA, Antholine WE & Kalyanaraman B 1999 Mechanism of superoxide
 490 dismutase/H₂O₂-mediated nitric oxide release from S-nitrosoglutathione - Role of glutamate.
 491 *Archives of Biochemistry and Biophysics* **372** 8-15.

492 Sun F, Bahat A, Gakamsky A, Girsh E, Katz N, Giojalas LC, Tur-Kaspa I & Eisenbach M 2005
 493 Human sperm chemotaxis: both the oocyte and its surrounding cumulus cells secrete sperm
 494 chemoattractants. *Human Reproduction* **20** 761-767.

495 Thundathil J, de Lamirande E & Gagnon C 2003 Nitric oxide regulates the phosphorylation of
 496 the threonine-glutamine-tyrosine motif in proteins of human spermatozoa during capacitation.
 497 *Biology of Reproduction* **68** 1291-1298.

498 Turner RM 2006 Moving to the beat: a review of mammalian sperm motility regulation.
 499 *Reproduction, Fertility and Development* **18** 25-38.

500 Weinberg JB, Doty M, Bonaventura J, Haney AF 1995 Nitric oxide inhibition of human sperm
 501 motility. *Fertility and Sterility* **64** 408-413.

502 Willipinski-Stapelfeldt B, Lubberstedt J, Stelter S, Vogt K, Mukhopadhyay AK & Muller D 2004
 503 Comparative analysis between cyclic GMP and cyclic AMP signalling in human sperm.
 504 *Molecular Human Reproduction* **10** 543-552.

505 Wink DA & Mitchell JB 1998 Chemical biology of nitric oxide: Insights into regulatory,
 506 cytotoxic, and cytoprotective mechanisms of nitric oxide. *Free Radicals in Biology and*
 507 *Medicine* **25** 434-456.

508 World Health Organization 2001 Laboratory Manual for the Examination of Human Semen and
 509 Sperm-Cervical Mucus Interaction. Cambridge: Cambridge University Press.

510 Yang JZ, Ajonuma LC, Rowlands DK, Tsang LL, Ho LS, Lam SY, Chen WY, Zhou CX, Chung
 511 YW, Cho CY *et al.* 2005 The role of inducible nitric oxide synthase in gamete interaction and
 512 fertilization: a comparative study on knockout mice of three NOS isoforms. *Cell Biology*
 513 *International* **29** 785-791.

514 Zhang H & Zheng RL 1996 Possible role of nitric oxide on fertile and asthenozoospermic
 515 infertile human sperm functions. *Free Radical Research* **25** 347-354.

516

Figure legends





Figure 1. Effect of GSNO on sperm motility patterns.

A. The percentage of spermatozoa exhibiting a forward progressive motility (A + B WHO classes) was recorded by computer-assisted sperm analysis (CASA) after a 30 min (white bars),

524 60 min (black bars) or 90 min (hatched bars) incubation of 20×10^6 cells /200 μ l with 0.1-10 μ M
525 S-nitrosoglutathione (GSNO). All data are presented as means \pm SEM (n = 25). Significance vs.
526 control at the corresponding incubation time: * $p < 0.05$.

527 B. The percentage of spermatozoa exhibiting a forward progressive motility (A + B WHO
528 classes) was recorded by CASA after a 10, 20, 30, 60 or 90 min incubation of 20×10^6
529 spermatozoa/200 μ l with 5 μ M GSNO. All data are presented as means \pm SEM (n = 4).
530 Significance vs. ctrl : * $p < 0.05$.

531



533

534

535

536

537

538


539

540

541

542

Figure 2. Effect of the modulation of the cGMP pathway on human sperm progressive motility. The forward progressive motility (motility classes A + B) was assessed by CASA in human spermatozoa ($20 \times 10^6/200 \mu\text{l}$) incubated for 30, 60 or 90 min with the following substances, alone or differently combined: S-nitrosoglutathione (GSNO, 5 μM), 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ, 10 μM), 8-bromo-cGMP (8-Br-cGMP, 500 μM), Rp-8-Br-cGMPS (Rp, 10 μM). All data are presented as means \pm SEM (n = 40). Significance vs. respective CTRL: * $p < 0.001$; vs. GSNO: ° $p < 0.001$; vs. GSNO+ODQ: § $p < 0.001$; vs. 8-Br-cGMP: ^ $p < 0.001$.




544

545

546 **Figure 3. Effect of GSNO, PTIO and IBMX on sperm motility patterns.** The forward
 547 progressive motility (motility classes A + B) was assessed by CASA in human spermatozoa
 548 ($20 \times 10^6/200 \mu\text{l}$) incubated for 30, 60 or 90 min with the following substances, alone or
 549 differently combined: 5 μM GSNO, 100 μM PTIO, 200 μM IBMX. In the case of IBMX, the
 550 spermatozoa were pre-treated for 20 min with IBMX before being incubated with 5 μM GSNO

551 for 30, 60 or 90 min. All data are presented as means + SEM (n = 4). Significance vs. respective
552 ctrl: * p<0.05; vs. GSNO: ° p<0.05.

553



555

556

557 **Figure 4. Effects of the modulation of the cGMP pathway on straight linear velocity (VSL,**
558 **panel A), curvilinear velocity (VCL, panel B) and average path velocity (VAP, panel C) of**

559 **human spermatozoa.** VSL, VCL and VAP were measured by CASA on human spermatozoa
560 ($20 \times 10^6/200 \mu\text{l}$) incubated for 30, 60 or 90 min in the absence (CTRL) or presence of the
561 following agents, alone or differently combined: 5 μM GSNO, 10 μM ODQ, 500 μM 8-Br-
562 cGMP, 10 μM Rp-8-Br-cGMPS (Rp). Results are shown as means \pm SEM (n = 40).


563 **A.** Significance vs. CTRL: * $p < 0.001$; vs. GSNO: $^{\circ} p < 0.001$; vs. GSNO+ODQ: $^{\S} p < 0.001$; vs.
564 8-Br-cGMP: $^{\wedge} p < 0.001$.

565 **B.** Significance vs. CTRL: * $p < 0.001$; vs. GSNO: $^{\circ} p < 0.005$; vs. GSNO+ODQ: $^{\S} p < 0.01$; vs.
566 8-Br-cGMP: $^{\wedge} p < 0.005$.

567 **C.** Significance vs. CTRL: * $p < 0.001$; vs. GSNO: $^{\circ} p < 0.001$; vs. GSNO+ODQ: $^{\S} p < 0.001$; vs.
568 8-Br-cGMP: $^{\wedge} p < 0.001$.

569

570



571

572

573

574

575

576

577

578

579

580

581

Figure 5. Intracellular cGMP levels in human spermatozoa treated with agents modulating the cGMP pathway. Sperm samples (15×10^6 cells/500 μ l) were pre-treated with 200 μ M IBMX for 20 min, and subsequently they were incubated for 30, 60 or 90 min in the absence (CTRL) or presence of the following substances, alone or in co-incubation: 5 μ M GSNO, 10 μ M ODQ, 500 μ M 8-Br-cGMP. Then, intracellular cGMP concentration was determined as described under the Materials and Methods section. The measurements were performed in triplicate, and data are presented as means \pm SEM (n = 5). Significance vs. CTRL: * $p < 0.001$; vs. GSNO: ° $p < 0.005$; vs. GSNO+ODQ: § $p < 0.001$.